

## **Product Innovation and Regulatory Affairs Committee Charter**

### **Membership**

The Product Innovation and Regulatory Affairs Committee (the “Committee”) of the Board of Directors (the “Board”) of Philip Morris International Inc. (the “Company”) shall consist of at least three directors chosen by the Board. Based on the recommendation of the Nominating and Corporate Governance Committee, the Board annually shall elect the members and the Chair of the Committee at its organizational meeting following the Annual Meeting of Stockholders. The members of the Committee may be removed by the Board.

### **Purpose**

The purpose of the Committee is to oversee the research and development of new products and to improve existing products, with a particular focus on Reduced-Risk Products, which is the term the Company uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. The Committee will also monitor key legislative, regulatory and public policy issues and trends related to the research and development of Reduced-Risk Products.

In furtherance of this purpose, the Committee will monitor:

- the Company’s internal scientific research, including the Company’s efforts to substantiate the risk-reduction potential of its RRPs through rigorous scientific methodologies, as well as the external body of scientific research relevant to the Company’s present and future Reduced-Risk Products;
- the Company’s development of innovative Reduced-Risk Products; and
- evolving risks affecting the Company’s research and development, which may include the risk that the regulatory environment will not differentiate between combustible products and RRPs, will limit consumer access to RRPs or to accurate information about their risks and benefits, and will limit the opportunity to switch smokers to RRPs; and risks associated with changes in consumer preferences regarding RRPs.

## **Procedures**

The Committee shall meet as often as it deems appropriate to carry out its responsibilities. A majority of the members of the Committee shall constitute a quorum. The Chair of the Committee, in consultation with the other Committee members, shall set meeting agendas. The Committee shall report its actions and recommendations to the Board.

Management will present to the Committee a description of and estimated budget for any proposed significant research and/or product development project. The Committee will consider whether to recommend to the Board that it approve the project within the context of the Company's original budget and long range plan. It will also consider from time to time whether to recommend to the Board that an ongoing project be terminated.

The Committee shall have the sole authority to retain and terminate any advisors to the Committee as the Committee may deem appropriate, including sole authority to approve related fees and terms of any advisors to the Committee that it retains.

The Committee may delegate its authority to subcommittees or the Chair of the Committee when it deems appropriate.